Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Set To Climb From $9.68 Billion In 2026 To $17.1 Billion By 2030
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market has seen significant growth in recent years. It is projected to expand from $8.41 billion in 2025 to $9.68 billion in 2026, achieving a compound annual growth rate (CAGR) of 15.1%. This market’s historical expansion can be attributed to factors such as COVID-19 vaccine initiatives, an increase in biotech startups, limited in-house manufacturing capabilities, a rise in contract manufacturing, and the rapid validation of mRNA platforms.
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market size is anticipated to undergo substantial expansion in the coming years. It is projected to achieve $17.1 billion in 2030 at a compound annual growth rate (CAGR) of 15.3%. This expansion during the forecast period stems from factors such as the broadening scope of mRNA cancer vaccines, an increase in personalized vaccines, more CDMO collaborations, the imperative for swift large-scale production, and an augmented pipeline of mRNA therapies. Noteworthy trends for this forecast duration include lipid nanoparticle formulation services, expedited mRNA process scaling, integrated fill finish outsourcing, adaptable modular vaccine manufacturing suites, and comprehensive end-to-end mRNA development services.
Get A Free Sample Report With In-Depth Market Insights:
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Demand Drivers: What’s Powering Industry Growth?
The increasing occurrence of infectious and newly developing diseases is projected to drive expansion within the mRNA vaccine CDMO market in the future. These diseases are defined as ailments stemming from disease-causing microorganisms, which either spread quickly or emerge unexpectedly due to factors like shifting environments, urban growth, and greater worldwide connections. Increased global travel, higher population densities, and linked supply networks have sped up the spread of pathogens, resulting in more frequent, extensive, and challenging-to-contain disease outbreaks. mRNA vaccine CDMOs are essential in confronting these issues, facilitating the swift creation, expandable production, and adaptable manufacturing of vaccines necessary to combat evolving infectious risks. Given that mRNA technologies demand specific manufacturing facilities and specialized technical knowledge, vaccine developers often engage contract development and manufacturing organizations to shorten development periods and guarantee manufacturing preparedness during outbreaks. For instance, in May 2024, according to the World Health Organization (WHO), a Switzerland-based United Nations’ specialized agency for global health, as of 30 April 2024, more than 7.6 million dengue cases were reported globally to WHO, including 3.4 million confirmed cases, over 16,000 severe cases, and more than 3,000 deaths. The increase has been particularly pronounced in the Region of the Americas, where cases exceeded seven million by April 2024, surpassing the 2023 annual total of 4.6 million cases. Consequently, the increased occurrence of infectious and emerging diseases is fueling the expansion of the mRNA vaccine CDMO market.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Segmentation: How Does The Market Break Down By Category?
The messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market covered in this report is segmented –
1) By Service Type: Process Development; Manufacturing; Analytical And Quality Control; Fill Finish; Packaging; Other Service Types
2) By Vaccine Type: COVID-19 Vaccines; Cancer Vaccines; Infectious Disease Vaccines; Other Vaccine Types
3) By Scale of Operation: Preclinical; Clinical; Commercial
4) By End-User: Pharmaceutical Companies; Biotechnology Companies; Research Institutes; Other End-Users
Subsegments:
1) By Process Development: Formulation Optimization; Cell Line Development; Upstream Process Development; Process Scale-Up
2) By Manufacturing: Lipid Nanoparticle Production; Enzymatic Capping; Purification Process
3) By Analytical And Quality Control: Potency Testing; Purity Analysis; Stability Testing; Identity Testing; Microbial Testing
4) By Fill Finish: Aseptic Filling; Vial Filling; Syringe Filling; Lyophilization
5) By Packaging: Primary Packaging; Secondary Packaging; Labeling Operations; Cold Chain Packaging; Unit Dose Packaging
6) By Other Service Types: Regulatory Support Services; Technology Transfer Services; Contract Development Services; Consulting Services; Supply Chain Management
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Innovation Trends: What Developments Are Reshaping The Industry?
Leading companies within the mRNA vaccine CDMO market are increasingly concentrating on advanced innovations, such as phase-appropriate GMP mRNA contract development and manufacturing services. This focus aims to accelerate preclinical and IND-enabling development while maintaining regulatory-aligned quality standards and achieving shorter timelines. Phase-appropriate GMP-like mRNA manufacturing refers to a production approach designed to deliver high-quality, regulatory-aware mRNA material suitable for preclinical and early development stages, without the cost and operational complexity associated with full GMP manufacturing. For instance, in May 2025, GenScript Biotech Corporation, a China-based global biotechnology reagents and services provider, launched a GMP-like mRNA manufacturing service specifically aimed at supporting preclinical and IND-enabling development. This service provides high-quality, regulatory-aware mRNA with reduced lead times and lower costs compared to traditional full GMP manufacturing, reflecting the growing demand for flexible, phase-appropriate CDMO solutions in the mRNA vaccine market.
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Competitive Landscape: Which Companies Lead The Industry?
Major companies operating in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market are Sanofi S.A., Thermo Fisher Scientific Inc., FUJIFILM Diosynth Biotechnologies U.S.A. Inc., Danaher Corporation, Boehringer Ingelheim BioXcellence GmbH & Co. KG, AGC Biologics A/S, Eurofins Scientific SE, Lonza Group AG, BioNTech SE, Samsung Biologics Co. Ltd., WuXi Biologics (Cayman) Inc., Siegfried Holding AG, Recipharm AB, Vetter Pharma International GmbH, CordenPharma GmbH & Co. KG, Ajinomoto Bio-Pharma Services Inc., Novasep Holding S.A.S., Rentschler Biopharma SE, IDT Biologika GmbH, Wacker Biotech GmbH
View The Full Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Report:
Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development And Manufacturing Organization (CDMO) Market Regional Outlook: Where Is Opportunity Concentrated?
North America was the largest region in the mRNA vaccine contract development and manufacturing organization (CDMO) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the messenger ribo nucleic acid (mrna) vaccine contract development and manufacturing organization (cdmo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
